Log in to save activitiesYour saved activities will show here so that you can easily access them whenever you're ready. Log in hereCME & EducationLog in to keep track of your credits.
Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
Early Disease Considerations in Triple Negative Breast Cancer CME / ABIM MOC / CEAre you looking to get up to speed about emerging research on ctDNA, systemic therapy, and managing toxicity in early-stage triple negative breast cancer? Learn more here.
Medscape Education Oncology, December 2022
Special Topics in HER2-Positive Breast CancerCME / ABIM MOC / CETop breast cancer experts cover the latest data on brain metastases in breast cancer, HER2-low breast cancer and HER2 testing.
Lung cancer is the leading cause of cancer death among both men and women; more people die from lung cancer than from colon, breast, and prostate cancers combined. In 2007, more than 200,000 people will develop lung cancer and more than 160,000 people will die from the disease. Incremental improvements are made regularly in the ways in which all treatment modalities (ie, surgery, radiation, and medical therapies) are applied to patients with lung cancer. Practitioners face a continuing challenge in staying on top of new data and recommendations based on recent advances in therapy. These advances include the incorporation of targeted therapies into traditional chemotherapy- and radiation-based regimens for lung cancer.
